[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-artery-occlusive-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-artery-occlusive-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100545993","leg-exercise-assistive-paddling-leap-therapy-for-peripheral-artery-disease-100545993",false,"NCT06389149","Leg Exercise Assistive Paddling (LEAP) Therapy for Peripheral Artery Disease","Inclusion Criteria:\n\nPAD subjects:\n\n* Able to provide written informed consent\n* 50-85 years of age\n* Diagnosed with Peripheral Arterial Disease (PAD) Fontaine stage II-III\n* Women must be postmenopausal (cessation of menses for \\> 24 months)\n* History of exercise-induced claudication\n* Free of ulcers, gangrene, or necrosis of the foot, Fontaine stage IV PAD\n\nAge-matched control subjects:\n\n* Able to provide written informed consent\n* 50-85 years of age\n* No evidence of peripheral occlusive disease, ankle-brachial index \\> 0.90\n* Women must be postmenopausal (cessation of menses for \\> 24 months)\n\nExclusion Criteria:\n\nPAD subjects:\n\n* Pain at rest and\u002For tissue loss from Peripheral Arterial Disease (PAD), Fontaine stage IV PAD\n* Acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma\n* Limited walking capacity from conditions other than PAD\n* Have not had a physical exam to assess exercise limitations in the past year\n* Pregnant or nursing\n* Kidney disease or type II diabetes mellitus\n\nAge-matched control subjects:\n\n* Positive diagnosis of Peripheral Arterial Disease (PAD)\n* Any exercise limitations as determined at last physical exam, at least 1 year prior to study\n* Have not had a physical exam to assess exercise limitations in the past year\n* Limited walking capacity from musculoskeletal injury\n* Pregnant or nursing\n* Kidney disease or type II diabetes mellitus",true,"ALL","55 Years","85 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to test the effects of leg exercise assistive paddling (LEAP) therapy during prolonged sitting (PS) on vascular and functional performance in those with peripheral artery disease (PAD) and age-matched controls. LEAP therapy is a novel application of passive limb movement to enhance blood flow through the legs without muscular contractions. Specifically, LEAP therapy is the rotational passive movement of the lower leg about the knee from 90 to 180 degrees of rotation at a cadence of 1Hz. Previous literature has indicated that this movement pattern can produce robust increases in blood flow in the passively moved limb in healthy individuals, and passive limb movement may protect vascular function during PS. However, the impact of LEAP therapy to improve blood flow in the legs of those with PAD during PS is unknown.\n\nParticipants will participate in a randomized cross-over design study with 2 visits (LEAP therapy and no LEAP therapy). For the first visit, participants will be randomly allocated to receive LEAP therapy during 2.5 hours of PS or not. For the second visit, participants will sit for 2.5 hours and will receive the condition that they did not previously receive. Before and after PS, the following measurements will be made: flow-mediated dilation of the popliteal and brachial arteries, arterial stiffness with tonometry techniques, microvascular vasodilatory capacity and skeletal muscle metabolic rate with near-infrared spectroscopy, autonomic nervous system function, and there will be blood drawn from the antecubital vein. After PS, participants will participate in a graded exercise test to assess functional walking capacity. Finally, during PS, near-infrared spectroscopy on the calf muscles and electrocardiogram will be collected continuously to monitor muscle oxygen availability and autonomic activity, respectively.",[27,28,29,30],"Peripheral Arterial Disease","Peripheral Vascular Disease","Peripheral Artery Occlusive Disease","Peripheral Artery Disease","RECRUITING","2025-09-29",{"date":34,"type":35},"2025-10-01","ACTUAL",{"date":37,"type":35},"2024-08-16",{"date":39,"type":21},"2026-08",{"name":41,"class":42},"University of Nebraska","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":43},"100589228","xeltis-peripheral-artery-disease-xpad-bypass-conduit-early-feasibility-study-100589228","NCT06951685","Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit Early Feasibility Study","Prospective, Non-randomized, Early Feasibility Clinical Study to Assess the Feasibility of the Novel Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit","Inclusion Criteria:\n\n1. Subjects with femoral artery occlusion who require elective above-knee femoral popliteal bypass surgery\n2. Patient has Rutherford grade 3, 4, or 5 occlusive vascular disease and TASC C or D lesions. Rutherford grade 5 may be included with a wound, ischemia and foot infection (WiFi) classification of up to grade 2, provided there are two outflow vessels with at least one reaching the pedal arch\n3. At least 18 years of age at screening\n4. Suitable anatomy (assessed by a pre-procedural contrasted CT scan or previous angiogram assessed up to 90 days prior to baseline)\n5. Patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent\n6. Patient has been informed and agrees to pre- and post-procedure follow-up, including follow-up angiography\n7. Life expectancy of at least 24 months\n\nExclusion Criteria:\n\n1. Subject requires, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure.\n2. Presence or history of bypass in the diseased limb\n3. Subject requires sequential extremity revascularizations or other procedures that require use of additional vascular grafts\n4. Stroke or myocardial infarction event within 6 weeks of the procedure or evidence of prior massive stroke (Modified Rankin Scale 3 or above)\n5. History of acute arterial occlusion requiring an emergent intervention\n6. Severe chronic renal insufficiency (serum creatinine \\>2.5 mg\u002FdL) or undergoing hemodialysis\n7. Previous renal transplant\n8. Uncontrolled arterial hypertension (BP \\>200 mmHg) at 2 successive readings\n9. Uncontrolled or poorly controlled diabetes\n10. Abnormal blood values that could influence patient recovery and or\u002F graft hemostasis\n11. Reduced liver function, defined as: \\>2x the upper limit of normal for serum bilirubin, International Normalized Ratio (INR) \\>1.5 or prothrombin time (PT) \\>18 seconds\n12. Any active local or systemic infection\n13. Known heparin-induced thrombocytopenia\n14. Known active bleeding disorder and\u002For any coagulopathy or thromboembolic disease\n15. Allergies to study device (nitinol) or agents\u002Fmedication, such as contrast agents or aspirin, that can't be controlled medically\n16. Previous enrolment in this study\n17. Subject is participating in another study\n18. Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives\n19. Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and performance of the study conduit\n\nIntra-operative exclusion criteria:\n\n1\\. Unsuitable anatomy to implant the XPAD conduit (e.g. target vessel diameter smaller than anticipated; severe calcification)","18 Years",{"count":53,"type":21},6,[24],"A prospective, single arm, non-randomized early feasibility study to evaluate the preliminary safety and performance of the XPAD conduit in patients with peripheral arterial occlusive disease (PAOD), scheduled to undergo elective above-knee femoral popliteal bypass surgery.",[29],"2025-07-09",{"date":59,"type":35},"2025-07-15",{"date":61,"type":35},"2025-05-02",{"date":63,"type":21},"2028-09",{"name":65,"class":66},"Xeltis","INDUSTRY",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":74,"targetDuration":76,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":43},"100445313","the-prevalence-survey-of-aldh-gene-family-in-patients-with-peripheral-arterial-occlusive-disease-or-acute-coronary-syndrome-100445313","NCT05078814","The Prevalence Survey of ALDH Gene Family in Patients With Peripheral Arterial Occlusive Disease or Acute Coronary Syndrome","Inclusion Criteria:\n\n1. Age≧20 y\u002Fo\n2. Using ankle-brachial index (ABI)\\\u003C 0.9, angiography, vascular duplex, CAT scan or cardiologists'impression to confirm the diagnosis of PAOD\n3. Clinical presentation of claudication\n4. diagnosis of ACS\n\nExclusion Criteria:\n\n* If the patient refuses to be included in this study","20 Years",{"count":75,"type":21},600,"2 Years","OBSERVATIONAL","Aldehyde dehydrogenase 2 (ALDH2) is an important enzyme protecting human from the accumulation of aldehyde, the main metabolites of alcohol. The deficiency of ALDH2 gene results in flush and hang over post drinking and most importantly it has been found associated with the incidence of cancer and post myocardial infarction (MI) heart failure. In the previous studies, ALDH2 decreased the ischemic territory post infarction and using a large scaled interaction of genetic variants and ALDH2 as an instrument, the threats of alcohol consumption on Asians' cardiovascular health was underscored. Furthermore, in a meta-analysis reviewing 12 case-control studies also indicated an increase of 48% risks in patients with ALDH2 deficiency. Notably, the genetic deficiency is most prevalent in Asians. In Taiwan one of every two individuals may be the victim and the high prevalence is counted as the top of the world. However, a large scaled prospective study focusing on the prevalence of ALDH2 deficiency in patients with peripheral artery occlusive disease (PAOD) or acute coronary syndrome （ACS）remains lacking.",[29,80],"Acute Coronary Syndrome",[82],"Peripheral Artery Occlusive Disease or Acute Coronary Syndrome","2021-10-01",{"date":85,"type":35},"2021-10-15",{"date":87,"type":35},"2018-03-01",{"date":89,"type":21},"2026-12-31",{"name":91,"class":42},"Chimei Medical Center"]